JAMES M. FRATES - 16 Jun 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Director
Signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for James M. Frates
Issuer symbol: SAGE
Transactions as of: 16 Jun 2021
Transactions value $: $99,735
Form type: 4
Filing time: 17 Jun 2021, 16:04:47 UTC
Previous filing: 11 Jun 2021
Next filing: 26 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Purchase	$99,735	+1,810		$55.10	1,810	16 Jun 2021	See Footnote 2	F1, F2
holding	SAGE	Common Stock						1,035	16 Jun 2021	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $55.08 USD to $55.11 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2	Represents 905 shares held directly by the John A. Frates 2013 Irrevocable Trust, dated December 19, 2013, and 905 shares held directly by the Peter E. Frates 2013 Irrevocable Trust, dated December 19, 2013. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

Content

This transaction was executed in multiple trades at prices ranging from $55.08 USD to $55.11 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Represents 905 shares held directly by the John A. Frates 2013 Irrevocable Trust, dated December 19, 2013, and 905 shares held directly by the Peter E. Frates 2013 Irrevocable Trust, dated December 19, 2013. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.